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Abstract 
Purpose: To determine the surface epitopes of Mycobacterium leprae (M. leprae) and evaluate their 
efficacy in the production of anti-M. leprae antibodies in an animal model.  
Methods: Blood samples were obtained from 34 patients suffering from lepromatous leprosy. 
Antibodies were obtained from the samples, semi-purified and used to coat the wells of ELISA 
microplate, and M13 random-peptides library was added to the wells. After four rounds of panning, three 
clones were isolated and their peptide mimotopes were sequenced. Western blot was used to evaluate 
the interaction of the isolated mimotopes.  
Results: Three selective clones were tested by direct enzyme-linked immunosorbent assay (ELISA) 
and western blot. anti-leprae antibodies in various dilutions and were found to be serological active. 
Sequencing of the isolated peptides showed identities between the two clones that were able to 
successfully induce anti-Leprae humoral response in mice.  
Conclusion: The findings indicate that the isolated peptides can potentially be used for early diagnosis. 
However, further research is required to improve their potency as new vaccines against leprosy. 
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Leprosy is a chronic granulomatous bacterial 
infection with M. leprae that principally affects the 
skin and the peripheral nervous system [1-2]. In 
endemic areas, the incidence of leprosy is 
estimated to be about 4 to 6 cases per thousand. 
The lipid-rich cell wall of pathogenic bacteria are 
likely responsible for their resistance and enable 
bacteria to escape from host defense 
mechanism.  
 
Leprosy treatment is difficult due to slow growth 
rate of the bacteria and long incubation period 
(average of 3-10 years). Additionally, multiple 
relapse and the emergence of drug-resistant 
strains have made the treatment more 
challenging. Such clinical prognosis correlates 
with the level of cell-mediated immunity (CMI) 
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against M. leprae. Antibody responses are great 
in lepromatous patients, indicating that humoral 
immunity does not contribute to the host defense 
[6]. 
 
On the other hand, full assessment of M. leprae 
antigenic structure is not possible due to lack of 
bacterial growth in culture media that has major 
contribution in the absence of suitable vaccine 
against leprosy [4]. The World Health 
Organization’s effort to eliminate leprosy by 2000 
was based on important advances achieved in 
anti-mycobacterial therapy in the 1980s. 
Although over the last decade, the dramatic 
reduction in prevalence of leprosy has been 
reported in most of the endemic countries, but its 
incidence rate is also high [3,5]. In this context, 
the IDEAL consortium Initiative for Diagnostic 
and Epidemiological Assays for Leprosy was 
established in 2004 and represents an 
international task-force that brings together 
researchers from endemic and non-endemic 
countries and aiming at the concerted 
development of diagnostic tests for early 
diagnosis of leprosy [5]. Identification of 
molecular markers improves epidemiological 
knowledge and transmission of leprosy that leads 
to intervention designing for prevention of the 
disease [3,7]. 
 
Display systems based on bacteriophages are 
widely used to assess different proteins and 
antibodies developed for identification of 
pathogenic bacteria [8-10]. A phage library that 
expresses random short peptide sequences on 
the surface of filamentous phage represents one 
of the biotechnological tools that could be helpful 
in amino acid sequence identification of various 
antigenic epitopes [11-13]. Panning the peptide 
phage library against a specific antibody results 
in isolation and identification of desired epitopes 
and their amino acid sequence and also 
determining the nucleotide sequence of genes 
expressing peptides on the phage surface 
[11,13,14]. 
 
In this research, the M13 random peptide phage 
library was used to detect the surface antigen 
epitopes of leprosy bacterium [15]. In addition to 
high efficiency, phage display systems are easy 
to work with and require no advanced 
techniques, expensive equipment or materials 
[16]. Isolated phage-peptides can be used for 
induction of immune response without use of 
adjuvants [17,18]. M13 phage is a filamentous 
bacteriophage and is one the most used display 
systems [16]. One of the important and unique 
features of the vectors derived from the M13 
phage is their potential for expressing short 
random peptide sequences on one of their coat 
proteins [16]. 
 
In this study, specific anti-M. leprae antibodies 
isolated from patients were used in panning 
against peptide phage library, This method can 
help to identify the functional epitope sequences 
and may contribute to development of a 







The Ph.D.™-12 Phage Display Peptide Library is 
based on a combinative library of random 
peptides fused on a minor coat protein (pIII) of 
M13 phage [20,21]. The peptide is linked to the 
pIII coat protein by a spacer (Gly-Gly-Gly-Ser). 
The library consists of approximately 2.8 × 109 
unique members, amplified once to yield 
approximately 70 copies of each sequence in 10 
µl of the supplied phage. 
 
Preparation of leprosy antiserum 
 
Antiserum was prepared from blood samples of 
34 leprosy patients in Lepromatous stage that 
were received from Center for Research and 
Training in Skin Disease and Leprosy. Plasma 
was separated from the blood clot after 
centrifugation at 1000 g at 4 °C. Serum samples 
of all 34 patients were pooled together and 
ammonium sulfate precipitation (final 
concentration 45 %) was used to increase the 
concentration of antibodies. After addition of 
sodium azide, the precipitated serum was 
distributed in 500 µL aliquots and kept at -20 °C. 
Protein concentration of samples were 




The phage library was titrated before panning. 
Serial dilutions of phage were prepared in LB 
broth (1 % Yeast extract, 1 % Tryptone and 1 % 
NaCl). Dilutions were added to E. coli ER2738 
and incubated at room temperature for 5 
minutes. The bacteria were mixed with Top agar 
(1 % Yeast extract, 1 % Tryptone, 1 % NaCl and 
0.75 % Agar) and plated on LB agar containing 
X-Gal (20 µg/mL) and Isopropyl thiogalactose 
(IPTG) (1 mM). The plates were incubated at 37 
oC for 16 h and numbers of colonies were 
counted to obtain phage pfu/mL. 
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The ELISA microplate wells were coated with 15 
µg of leprosy antiserum in 150 µL volume of 100 
mM sodium bicarbonate buffer (pH 8) and 
incubated overnight at 4 oC. The wells were 
washed using TBS (50 mM Tris-Cl, 150 mM 
NaCl, pH 7.5) and blocked using 200 µL of 100 
mM sodium bicarbonate buffer containing 3 % 
BSA and incubated at 37 oC for 1 h. Wells were 
then washed six times using TBS containing 0.05 
% Tween 20 (TBST). A total of 4 × 1010 Phages 
were diluted in 1 ml of TBST buffer and 100 µL 
was added to each well. The microplate was 
incubated at room temperature for 1 h. The 
supernatant was discarded and the wells were 
washed 10 times with Tris-Buffered Saline and 
Tween 20 (TBST) buffer. For eluting the bound 
phages, 100 µL of glycine and BSA buffer (100 
mM HCl-Glycine, pH 2.2) was added to the wells 
and the plate was incubated at room temperature 
for 15 min. Finally, 15 µL of 1 M Tris buffer (pH 
9.1) was added to each well for neutralization of 
glycine buffer. 
 
Phage multiplication  
 
One microliter of isolated phages was added to 
200 mL of fresh bacterial suspensions at mid log 
phase and incubated for 4.5 h at 37 ° C. It was 
centrifuged at 10000 g for 10 min at 4 °C. The 
supernatant was saved and mixed with 20 % 
(v/v) PEG/NaCl solution (16 % Polyethylene 
glycol in 2.5 M NaCl) and incubated on ice for 16 
h. The Phage/PEG/NaCl solution was 
centrifuged at 15000 g for 20 min. The phage 
sediment was resuspended in 1 mL TBS solution 
and stored at 4 oC for further application. To 
obtain the highest affinity binders, panning 
procedure (“Screening” and “Phage 
multiplication” steps) was repeated three or more 
times. Eluted phages from previous round were 
used for each panning round. 
 
Clone selection  
 
The phages after the fourth panning round were 
used for selecting specific clones with high 
affinity obtained leprosy antiserum.  
 
For selection of specific clone, 100 µg of patient 
anti-serum, normal anti-serum and BSA (5 
mg/ml) blocking buffer was separately added to 
the wells in duplicate and the plate was 
incubated 16 h at 4 oC. 
  
Serial dilution was prepared from phages purified 
from all selected clones. For each clone, 1×1012 
phage were diluted in a volume of 200 ml and 
then diluted 12 times by a factor less than 4, until 
number of phages reached 2 × 105 pfu/mL.  
 
After washing and blocking the wells, 100 µl of 
the diluted phages were added to each well and 
the plate was incubated at 37 oC for 1 h. Wells 
were washed and 200 µl of the anti-M13 
antibody (New England Biolabs, UK) diluted in 
the blocking buffer (1:5000) was added to each 
well. After 1 h incubation at 37 oC, the wells were 
washed 6 times with TBST buffer. Finally, 15 min 
after addition of the ABTS substrate (2, 2'-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt) (Sigma, Germany) dissolved in 
sodium citrate buffer the resulting color was read 
at 405-415 nm by ELISA reader. The clones with 
high absorbance compared with the normal 
serum and BSA were considered as positive 
clones. 
 
Western blot analysis 
 
To confirm phage expression of the peptides, 10 
% SDS-PAGE was used and the proteins 
transferred onto nitrocellulose membrane using a 
semi-dry transfer apparatus (ATTO Co. Japan), 
and thereafter incubated by polyclonal Anti-M. 
leprae MLMA-LAM (Rabbit antiserum, BEI 
Resources). The secondary antibody (HRP-
conjugated rabbit anti-IgG antibody, Abcam), 
diluted in the blocking buffer, was added. After 
washing the membrane with TBST for 15 min, 
detection was performed using DAB 




Six weeks old Balb/c mice (15-18 g) were used 
to evaluate the immunogenicity and specificity of 
the peptide in induction of anti-M. leprae 
antibodies.  
 
The experiment included 6 groups each of 5 
mice. The mice in groups 1, 2 and 3 were 
injected with 200 µl of 1 × 1013 cfu /mL of clone 
6, 9 and 10, respectively. Groups 4 and 5 were 
considered as positive controls and were 
respectively injected with 100 μg of Lepromin 
(ML) and Mycobacterium extract (M) in 200 μL 
PBS. Group 6 was the negative control and each 
mouse in the group was injected with the wild 
M13 bacteriophage in the same amount as 
groups 1 to 3. All injections were carried out 
intraperitoneally. First booster was injected after 
3 weeks and the rest of injections were done with 
2 week intervals. The immunization process was 
assayed by indirect ELISA. M. leprae extract was 
used to coat the ELSA microplate wells. Sera 
obtained from the mice were used as primary 
antibody and anti-mouse IgG antibody 
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conjugated with HRP (AbCam, UK) was used as 
a secondary antibody. 
 
Sequence determination  
 
To determine the genetic sequence of the 
peptides, 100 µL of positive sample mixed in TE 
buffer (1 × 1013 cfu/mL) was sequenced by 
primers of 12-mer Peptides of Phage Display 




One-way analysis of variance (ANOVA) was 
used to assess differences in the binding of 
phage-peptide to the test serum, control serum 
and BSA. The data are presented as mean ± 
standard deviation and compared using 






The clones were selected from the 4th round. 
Study of optical absorptions showed that only 3 
clones namely; 1, 6, and 9, had notable binding 
difference between the test serum, control serum 
and BSA, and showed the highest affinity toward 
leprosy antiserum. Results show that most 
clones do not show significant binding 
differences between the control groups, the test 
serum and BSA. However, significant difference 
was observed in comparison of the control 
groups and test serum in three clones 1, 6 and 9 




The size of pIII coat protein was about 45 kDa 
and can be seen in 45 to 65 kDa range. There 
were several specific bands within that range that 
were not observed in the positive and negative 
controls. These bands are not observed in clone 
6. Indeed, clone 6 could not elicit specific anti-M. 
leprae antibody response in the animal tests. The 
lighter bands could be as a result of protein 
degradation during the extraction process or 
cross-reaction. Finally, clones 1 and 9 were 
accepted as positive (Figure 1). 
 
 
Table 1: Analysis of ELISA results performed on test and control sera, and BSA at a dilution of 2 × 105 cfu/mL 
 
Subject Source of variant Mean square Sum of squares df FC 
  
Patient Serum 
Between Groups (Treatment) 1.279 12.793 10 171** 
Within Groups(Error) 0.007 0.164 22  
 Normal Serum Between Groups (Treatment) 0.004 0.041 10 1.641 Within Groups(Error) 0.003 0.055 22  
BSA Between Groups (Treatment) 0.002 0.020 10 1.902 Within Groups(Error) 0.001 0.023 22  
*Significant at 1% probability 
 
Fig 1: Western blot analysis on selected clones. Lane 
1: Standard protein Marker. Lane 2: Protein extracted 
from wild type M13 bacteriophage. Lane 3: cell 
extracts of Mycobacterium Leprae. Lanes 4, 5 and 6: 





Clone 6 showed immunogenicity only in one 
round; however, clones 1 and 9 produced 
specific anti-M. leprae immunity in all repeats 
Table 2. Groups 5 and 6 which were immunized 
with M and ML form respectively, were used as 
positive controls and were able to induce high 
immunity. Group 6 is the negative control group  
injected with wild type M13 showed no specific 
immune response against M. leprae antigens. 
Following the results of immunogenicity, the 
clones positive were sequenced. Nucleic acid 
sequences of clones 1 and 9 are shown in Table 
3. 
 
Phage-peptides (1, 6 and 9), Wild type M13 (10), 
M. leprae extract (M) and Lepromine (ML) were 
used to evaluate of specific immune response 
induction in mice.  Three repeats were carried 
out. Clones which were able to induce anti-M. 
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leprae antibodies were sequenced As shown the 




In the current study we achieved high affinity 
peptides (epitopes) that expressed on the 
surface of phage and are able to bind anti-M. 
leprae specific antibodiesFinally, two clones 
showed potential immunogenicity in mice. Lack 
of immunogenicity in the clone 6 may be 
because of phage mutation or immune system 
default of mice models that could not able to 
recognize this peptide as an antigen.  However, 
clones 1 and 9 were able to induce specific 
antibodies which are able to react with M. leprae 
antigens, thus these mimotope peptides have 
potential applications as a vaccine against the 
disease or may be applied as a diagnostic tool 
for leprosy cases. Despite that the 
immunogenicity mechanism is unknown, the 
antibody titer was considerably high. Given the 
amount of lepromin used in this study, the 
immune response of the peptides was equal to 
those of the positive control groups. The 
obtained immunotopes would thus be suitable for 
the preparation of sub-unit vaccine candidates 
against leprosy, or can be used in a more 
complex form to include cellular immunity 
response. Furthermore, the monoclonal 
antibodies achieved against these peptides can 
be used for development of accurate diagnostic 
tests.  
 
In this study, 11 plaques were randomly selected 
and analyzed for expression of foreign peptides, 
positive single clones sent for sequencing. 
Results of sequence identification in clones 1 
and 9 showed that the both clones have same 
sequence that could explain the western blotting 
binding pattern. The specificity of obtained 
sequence was confirmed by NCBI-Blast software 
[24,25].  
 
Leprosy diagnosis is mainly based on symptoms 
and clinical studies and there is no laboratory 
test to diagnose or predict the disease 
progression in individuals at risk [26]. There are 
two forms of disease caused by M. leprae. The 
specific antibody titer is low in tuberculoid 
paucibacillary leprosy (PB) but strong Th1/IFN-γ 
response that the role of cellular immunity (CMI) 
is significant. In the lepromatous multibacillary 
patients (MB) the antibody titer is high and the 
cell-mediated immunity (CMI) is low. Thus the 
(PB) and (MB) laboratory tests for the leprosy 
diagnosis are based on measuring the cell-
mediated immunity and antibodies. However, the 
laboratory tests should detect (PB) and (MB) 
forms. These require proteins with specific 
properties. These proteins can be obtained by 
recombinant or synthetic techniques [3,7]. 
Production of Lepromin requires bacterial culture 
and animal immunization, in our study we were 
able to produce peptides that can induce the 
same immune response as Lepromin, 
    Table 2: Immune response against mimotope peptides in animal models 
 
ML M 10 9 6 1 Immunized with → Experiment repeat ↓ 
+ +  - +  - + 1 
+ +  - + + + 2 
+ +  - +  - + 3 
 
Table 3: DNA sequences of selected recombinant phages 
 
Amino acid sequence of 
epitope Nucleotide acid sequence of epitope Positive clone 
LEQCQES 5′- CTC GAG CAA TGC CAA GAA TCG -3′ Clone-1 
LEQCQES 5′- CTC GAG CAA TGC CAA GAA TCG -3′ Clone-9 
 
thus the purified peptide has the potential to 
replace lepromin in research and therapy [15,26]. 
 
The methods based on IFN-γ and T-cell are not 
able to detect sub-clinical disease, and patients 
at the early stages of treatments. Moreover (PB) 
and (MB) forms cannot be distinguished [3,7]. It 
is ideal to use the peptides specific to M. leprae, 
recombinant or synthesized proteins in IFN-γ and 
T-cell methods. It is important to differentiate 
between the two (PB) and (MB) phases. These 
require access to the antigens of the bacteria 
which is complicated with respect to the 
difficulties in culturing and antigen isolation from 
M. leprae.  
 
In this study, the phage clones were selected 
from the phage library panned against antibodies 
isolated from lepromatous multibacillary (MB) 
stages. This stage has been selected due to high 
levels of antibodies against the disease. Also, by 
accessing specific peptides, patient identification 
by early diagnosis of infection would be possible 
by evaluation of specific cellular immunity (CMI) 
against leprosy [3].  
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However, given the genetic diversity of people 
and variety in HLA classes, feasibility of the 
methods for producing peptides that could result 
in production of high affinity antibodies that leads 
to use of diverse and rich pool of antibodies 
isolated from various people to include genetic 
diversity [25]. Accordingly, the antibodies used 
for panning in this research were extracted from 
a total of 34 patients and pooled to include most 
HLA varieties.    
 
M13 random phage peptide library was used 
against antibodies from leprosy patients to 
isolate the peptides mimicking the immunogenic 




This work identifies peptides which bind with high 
affinity to antibodies against M. leprae. Following 
injection of peptides to the mice model, the 
monoclonal antibodies produced can facilitate 
the development of serological diagnostic kits for 
detection of this bacterium and disease. 
Furthermore, the peptide may be used for the 
development of a new generation of vaccines 
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